Icahn Nominates Four for Forest Board in Second Fight
This article is for subscribers only.
Investor Carl Icahn nominated four directors to the board of Forest Laboratories Inc. in a second proxy fight against the drugmaker.
Icahn nominated Eric Ende, president of Ende BioMedical Consulting Group and a former biotechnology analyst at Merrill Lynch; Andrew Fromkin, the former chief executive officer of Clinical Data Inc., acquired last year by Forest; Pierre Legault, president and CEO of Stone Management LLC and a former chief financial officer for OSI Pharmaceuticals Inc.; and Daniel Ninivaggi, president of Icahn Enterprises, according to regulatory filing today.